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Abstract 
Renal transplantation is well established as the optimal form of renal replacement therapy 
but is restricted by the limited pool of organs available for transplantation. The whole organ 
decellularisation approach is leading the way for a regenerative medicine solution towards 
bioengineered organ replacements. However, systematic pre-optimisation of both 
decellularisation and recellularisation parameters is essential prior to any potential clinical 
application and should be the next stage in the evolution of whole organ decellularisation as 
a potential strategy for bioengineered organ replacements. Here we have systematically 
assessed two fundamental parameters (concentration and duration of perfusion) with 
regards to the effects of differing exposure to the most commonly used single 
decellularising agent (sodium dodecyl sulphate/SDS) in the perfusion decellularisation 
process for whole rat kidney ECM bioscaffolds, with findings showing improved preservation 
of both structural and functional components of the whole kidney ECM bioscaffold. Whole 
kidney bioscaffolds based on our enhanced protocol were successfully recellularised with 
rat primary renal cells and mesenchymal stromal cells to yield highly viable constructs. 
These findings should be widely applicable to decellularised whole organ bioscaffolds and 
their optimisation in the development of regenerated organ replacements for 
transplantation. 
 
  
Introduction 
End stage renal failure is associated with major morbidity and mortality[1]. Renal 
transplantation is well established as the optimal form of renal replacement therapy (RRT) 
but is restricted by the limited pool of organs available for transplantation from deceased 
donors. According to the UK Renal Registry, there were 53027 adult patients receiving RRT 
on 31/12/2011 in the UK but the total number of kidney transplants performed in 2011 was 
2752[1]. While a number of other approaches have been taken to attempt to artificially 
replace the functions of native kidney[2-8], recent innovations in the field of tissue 
engineering such as whole organ decellularisation may lead to a successful regenerative 
medicine approach and bioengineered solution to this pressing clinical need[9-11]. Whole 
organ decellularisation provides a relatively new approach to ‘whole organ’ engineering and 
this technique utilises the intrinsic vasculature to perfuse the decellularising agent and 
efficiently penetrate tissue and remove cellular material. The decellularised extracellular 
matrix (ECM) bioscaffold thus created preserves the intrinsic properties of the ECM[12] 
along with its natural organisational complexity in order to promote recellularisation and 
cellular differentiation on a whole organ level. The inherent vasculature is also critical in 
allowing perfusion to sustain cell culture in complex 3-D constructs. This approach has been 
successfully employed in the major solid organs to create viable and partially functional 
organ constructs, some of which have been implanted in vivo[13-18]. In particular recent 
work on the regenerated rat kidney has demonstrated up to 10% functionality in terms of 
urine production and creatinine clearance[18].  
While the potential clinical implications are extremely exciting, a number of major technical 
factors and challenges exist before clinical application can be considered. One critical group 
of pre-optimisation parameters lies with the production of the ECM bioscaffold and the 
decellularisation process. While the tissue- and organ-specific functional and bio-inductive 
molecules of the ECM are intrinsic to the success of the recellularisation and regenerative 
process, the quality of the ECM not only varies with each donor but also with each protocol 
applied[19]. A few studies have started to assess or compare effects of perfusion 
decellularisation protocols in a more systematic manner e.g. different decellularising 
agents[20], duration/exposure to the decellularising agent[21], but not in the rat kidney 
model. We have also shown in a recent systematic review that currently there can be 
significant disparity between decellularisation protocols in the literature even for the same 
organs/species, strongly suggesting the need for a more widespread evidence-based 
approach[22]. There are many parameters that exist to be considered – such as choice of 
decellularising agent (which also depends on type of tissue being decellularised), 
concentration and duration of perfusion (i.e. exposure) of decellularising agent on the 
tissue/ECM, additional steps in the protocol (e.g. freezing, use of biological agents), tissue 
harvesting factors, perfusion versus non-continuous, perfusion pressure versus perfusion 
rate, and last but not least, post-processing sterilisation methods.  
On this basis, we aimed to optimise two fundamental parameters  (i.e. concentration of 
decellularising agent and duration of perfusion) in order to assess the effects of differential 
exposure to decellularisation agent for whole rat kidney ECM bioscaffolds, using the most 
commonly reported single decellularising agent i.e. sodium dodecyl sulphate (SDS)[22]. 
Optimisation was determined with regards to structural and functional characteristics of the 
ECM bio-scaffold as assessed by histology, immunohistochemistry (IHC), quantitative assays 
of DNA and sulfated glycosaminoglycan (sGAG) content, and growth factor quantification – 
and optimisation was continued until a ‘plateau’ effect (‘no further comparative benefit’?) 
was observed in one or more of these modalities. We have also performed perfusion-based 
recellularisation of these whole rat kidney ECM bioscaffolds with rat primary renal cells and 
mesenchymal stromal cells to demonstrate high levels of cellular engraftment and cellular 
viability with in vitro perfusion culture, and formation of renal-like structures on histology. 
 
Methods and materials 
Decellurisation of whole kidneys 
1. Tissue harvesting 
Male Wistar rats (350-375 g, Charles River/UK) were chosen for kidney harvest for 
perfusion decellularisation. Briefly, renal arteries were cannulated immediately after 
euthanisation of the animal and perfused with phosphate buffered saline (PBS) with 
vasodilator (10 ml of 10 g/ml sodium nitroprusside in PBS, Sigma/UK, followed by 
20 ml at 1 g/ml) until a uniform blanching was observed, after which each kidney 
was perfused with 30 ml PBS without vasodilator. 
2. Whole kidney decellularisation 
Kidneys were suspended within a reservoir and perfused continuously via the 
arterial cannula at 10 ml/min, recirculating the total volume of 400ml of 
decellularising solution throughout the decellularisation process. The perfusate was 
sodium dodecyl sulfate (Sigma/UK) at differing concentrations and durations (see 
Tables 1a + 1b). After decellularisation, kidney bioscaffolds were perfused with PBS 
for 1 hour. Those for subsequent recellularisation were sterilised with 1% w/v 
antibiotic-antimycotic (Gibco®, Invitrogen/UK) in sterile PBS for 18 hours at 2 
ml/min. 
3. Histology and immunohistochemistry (IHC) 
All histological samples were fixed in 10% v/v buffered neutral formalin and stained 
with haematoxylin and eosin (H+E) for light microscopy.  
IHC was performed to assess retention of key ECM and basement membrane 
proteins collagens I and IV, laminin and fibronectin (all Abcam/UK). All samples were 
treated identically with regards to fixation, antigen retrieval, antibody staining, 
blocking and development. Briefly, paraffin-embedded sections were dewaxed and 
blocked with 1% v/v hydrogen peroxide in methanol for 10 minutes. Heat-mediated 
antigen retrieval was performed in 0.01M sodium citrate buffer (Sigma/UK), pH 6.0, 
followed by Avidin-Biotin blocking (Dako/UK). Sections were blocked for 1 hour with 
5% v/v goat serum in PBS, and primary antibodies were incubated overnight at 4oC. 
Primary antibody dilutions in blocking solution (5% v/v goat serum in PBS) were: 
collagen I 1:250, collagen IV 1:500, laminin 1:50, and fibronectin 1:500 (Abcam/UK). 
After washing sections in 0.1% v/v TWEEN (Sigma/UK) in PBS, pH 7.4, hydrogen 
peroxidase conjugated secondary antibody (Abcam/UK) was applied at 1:100 for 1 h 
at room temperature then washed again in TWEEN solution. Slides were developed 
using 3,3’-diaminobenzidine (Dako/UK) until good staining intensity was observed. 
Species immunoglobulin and PBS served as negative controls. Haematoxylin was 
used for nuclear counterstaining.  
4. DNA/sGAG quantification 
Approximately half of a whole, unfixed rat kidney or kidney bioscaffold was 
suspended within 5 ml of papain solution (55 mM L-cysteine hydrochloride, 80 mM 
EDTA, 2.5 units/ml papain, pH 6.0, all Sigma/UK) for 24 h at 60oC until no visible solid 
material remained. After digestion, the solution was freeze-dried for 24h using the 
Heto PowerDry LL1500 freeze dryer (Thermo Scientific/UK) to ascertain the dry 
weight.  
Total DNA content was quantified using the Picogreen® dsDNA assay (Invitrogen/UK) 
and total sGAG content was quantified using the Blyscan™ sGAG assay (Biocolor/UK) 
according to the manufacturer’s instructions. Each assay was performed in duplicate 
and three times in total.  
5. Growth Factor extraction and quantification assays 
Approximately half of a whole, unfixed rat kidney or kidney bioscaffold was 
suspended in ~3.75 ml of urea–heparin extraction buffer (2 M urea and 5 mg/ml 
heparin in 50 mM Tris with protease inhibitors: 1 mM phenylmethylsulfonyl fluoride, 
5 mM benzamidine, and 10 mM N-ethylmaleimide at pH 7.4, all Sigma/UK). The 
extraction mixture was rocked at 4°C for 20-24 h then centrifuged at 5,000 x g for 30 
min; supernatants were collected. 6 ml of extraction buffer was added to each 
pellet. These were again rocked at 4°C for 20-24 h, centrifuged at 5,000 x g for 30 
min, and supernatants collected. Supernatants from both extractions were dialyzed 
against ultrapure filtered water (total of three changes of dialysis water, 80-100 
volumes/change) in Spectra/Por 3500 MWCO dialysis membrane (Spectrum 
Lab./USA). Extracts were frozen in aliquots at -80˚C until assayed. Total protein 
concentration in each dialyzed extract was determined by the BCA protein assay 
(Pierce, Thermo Scientific/UK) following the manufacturer’s protocol. Basic fibroblast 
growth factor and vascular endothelial growth factor concentrations were 
determined with the Quantikine Human FGF basic Immunoassay and Quantikine Rat 
VEGF Immunoassay (R&D Systems/UK) respectively, following the manufacturer’s 
protocols. Each growth factor assay was performed in duplicate three times.  
It should be noted that each growth factor assay measured growth factor protein 
concentration and did not measure growth factor activity. 
6. Vascular resin corrosion casting  
A 0.5-1.0 ml volume of polymer mixture, depending on the kidney size, was injected 
via the arterial cannula using Batson’s no. 17 anatomic corrosion casting kit 
(Polysciences Inc./USA) as recommended by the manufacturer. Polymerisation took 
20-30 min at 4oC and photographic images were taken during the injection process 
over 10-30 seconds. 
7. Statistical analysis 
Results were reported as mean +/– standard error. Statistical analysis was 
performed with analysis of variance which demonstrated non-parametric 
distribution of data followed by Mann Whitney two sample test. A p-value of < 0.05 
was considered significant. 
 
Recellularisation of the whole kidney bioscaffold 
1. Recellularised kidney graft perfusion – system setup  
After sterilisation, the decellularised kidney bioscaffold was seeded with 50 x 106 
cells in divided multistep bolus injections via the arterial cannula at 45-60 minute 
intervals. Typically three injections of approximately 16 x 106 cells at 32 x 106 
cells/ml were used. The recellularised kidney bioscaffold was then suspended in the 
main chamber of a sterile three-port flask immersed within the reservoir of culture 
medium (150-180 ml volume). The perfusion system also included a sterile exchange 
membrane (BugStopper, Whatman/UK) and a peristaltic pump. The system was 
placed inside a standard 37oC 5% CO2 incubator for temperature and CO2 control. 
The graft was continuously perfused at 1.5 ml/min. The culture medium was 
changed every 48 h throughout the 7 day culture period (the first change occurring 
at 24 hours post-seeding).  
The perfusate consisted of either i) 50% DMEM and 50% Keratinocyte Serum-Free 
Medium (K-SFM) with bovine pituitary extract (BPE) and epidermal growth factor 
(EGF) with the addition of 5% v/v foetal bovine serum (FBS) and 1% v/v antibiotic-
antimycotic (AA) for primary renal cells, or ii)-MEM with the addition of 10% v/v 
FBS and 1% v/v AA (all Gibco®, Invitrogen/UK) for mesenchymal stromal cells. 
2. Primary renal cell (PRC) isolation 
Four-week-old Wistar rats were used for PRC isolation (protocol adapted from 
Joraku et al[16]). Briefly, minced kidney tissue from culled animals was digested in 
collagenase solution (Liberase TM Research Grade, Roche/UK) according to the 
manufacturer’s recommendations. The digested tissue suspension was filtered 
through a 100 m cell strainer (BD Falcon®, Corning/UK) and neutralised with an 
equal volume of DMEM culture medium. This solution was then centrifuged at 1200 
rpm for 5 minutes. The resulting cell pellets were re-suspended and plated in 50% 
DMEM + 50% K-SFM with BPE/EGF with the addition of 5% v/v FBS and 1% v/v AA. 
PRCs were passaged when they reached 95% confluence and typically used for 
recellularisation at P2 stage. 
3. Mesenchymal stromal cell (MSC) isolation 
Male Wistar rats (350-375g) were used for MSC isolation. Briefly, sterile femurs from 
culled rats were irrigated (by manual injection) through the diaphysis with culture 
medium (-MEM) and the resulting cell suspension plated in-MEM with 10% v/v 
FBS and 1% v/v AA. MSCs were passaged when they reached 95% confluence and 
typically used for recellularisation at the P2 stage. 
4. LIVE/DEAD™ staining 
The tissue sample was washed with PBS, and then completely immersed in the 
working solution (20 l of Ethd-1 and 10 l of calcein (Invitrogen/UK) in 10 ml of 
sterile PBS). This solution was incubated with the tissue sample for a period of 10-15 
minutes while being protected from light, then aspirated. The sample was washed 
three times with PBS and examined using fluorescent microscopy.  
5. AlamarBlue® assay 
A working solution of 1:10 alamarBlue® reagent (Invitrogen/UK) in culture medium 
was added directly to the tissue to completely immerse the sample. Samples and 
controls (working solution without tissue sample) were incubated for 4 hours at 37°C 
in 5% CO2 incubator. Each assay was performed in triplicate. Results were reported 
as mean +/– standard error. 
6. Histology and IHC 
All samples were fixed in 10% v/v buffered neutral formalin, and samples were 
stained with haematoxylin and eosin (H+E) for light microscopy.   
IHC was performed to characterise cell types and their distribution on the 
recellularised kidney bioscaffolds; the protocol is the same as above. Primary 
antibody dilutions were: aquaporin-1, aquaporin-2, synaptopodin, and von 
Willebrand Factor (all Abcam, UK) – all at 1:500. 
 
For all experimental work as described above, n ≥ 3.  
Results 
Optimisation of perfusion decellularisation in whole rat kidneys 
We have decellularised cadaveric whole rat kidneys using perfusion decellularisation via the 
renal artery with SDS initially at 1% concentration performed for decreasing durations of 
continuous perfusion (24 down to 4 hours) at 10 ml/min with 1% w/v SDS (Table 1a), which 
all yielded well decellularised bioscaffolds on histological analysis (Supplementary Fig. 1). 
Decellularisation was characterised by: histology and IHC, DNA and sGAG quantification, and 
growth factor (vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF)) quantification. The 1% w/v SDS x 4 hours protocol was denoted the baseline 
protocol for further comparisons. Two further series of protocols were carried out in 
decreasing concentrations of SDS (0.5%, 0.25%, and 0.125% w/v) and for two durations of 
perfusion (4 hours and 8 hours, Table 1b). All further decellularisation protocols were 
characterised similarly to the baseline protocol. 
 
Histology and IHC  
Histological analysis of perfusion decellularised kidney bioscaffolds shows preservation of 
the structure and architecture of the renal ECM within the acellular parenchyma (Fig. 1), as 
has been previously shown[18, 23, 24]. The preservation of the arterial network within the 
whole kidney bioscaffolds was also demonstrated with injection of a resin polymer for 
vascular casting (Fig. 2). Immunohistochemical staining for key ECM components (collagen I, 
collagen IV, laminin and fibronectin) shows a physiological distribution as compared to the 
normal kidney tissue control (Fig. 1). There were no gross differences observed between any 
of the protocols (variation in % SDS or duration of perfusion) in terms of the histological 
appearance and IHC staining (see also Supplementary Fig. 2 for full range of conditions 
analysed).  
 
Quantification Assays  
For all protocols, DNA levels in the decellularised kidney bioscaffolds (Fig. 3c) were ≤0.02% 
of normal kidney DNA content. Quantification of sGAG levels (Fig. 3a, b) show an at least  
two-fold increase in the average levels of sGAG preserved between the 4 hour and 8 hour 
protocols (p < 0.005).  
Levels of VEGF and bFGF preserved within the kidney ECM (Fig. 3d-f, g-i) were similar in that 
the 8 hour levels for both growth factors were significantly decreased compared to both 
normal kidney and the 4 hour protocols, and were in fact almost negligible for both. 
However, the levels of both growth factors were well preserved compared to normal kidney 
in the 4 hour series (3d-e, g-h), with the highest levels of preservation seen at the lowest 
concentration of SDS exposure i.e. 0.125% w/v in both VEGF and bFGF (p < 0.05). A clear 
trend of increasing levels of bFGF preserved as the concentration of SDS decreases can also 
be seen; however a plateau effect can be observed with both VEGF and bFGF as the 
difference observed between levels with 0.25% w/v SDS and those with 0.125% w/v was not 
significant (p = 0.256 for both). Group variations were noted in the levels obtained for all the 
quantification assays which are likely to be due to batch variation. 
 
Recellularisation of whole kidney bioscaffolds 
To recellularise the acellular whole kidney bioscaffolds for in vitro culture, these were 
injected intravascularly with two cell populations in parallel studies: primary renal cells 
(PRCs) isolated from 4 week old Wistar rats and adult Wistar rat bone marrow-derived 
mesenchymal stromal cells (MSCs). After the cell seeding process, perfusion was maintained 
at 1.5ml/min for the designated 7 day culture period. 
 
PRC-recellularised constructs 
Cellular viability tests (Fig. 4a, b) after 7 days of in vitro culture demonstrate continued and 
extensive viability throughout the 3-D kidney construct, with obvious cellular ‘patterning’ 
following the vascular network and also ECM structural cues on LIVE/DEAD™ staining.  
Histological analysis showed cellular engraftment dispersed throughout the kidney ECM 
bioscaffolds which was not restricted to the vascular compartment. Focal areas of 
recellularisation comparable to normal histological density were present throughout and 
distinctive ‘glomerular-like’ structures are easily observed (Fig. 5a). IHC of renal cell markers 
(aquaporin 1 and aquaporin 2 for tubular cells, synaptopodin and von Willebrand factor for 
glomerular epithelial and endothelial cells respectively) demonstrated the presence of 
mixed cell types throughout the recellularised construct (Fig. 5b). 
 
MSC-recellularised constructs 
Cellular viability tests (Fig. 4a, b) after 7 days of in vitro culture were similar to the PRC 
constructs: extensive viability throughout the 3-D kidney construct, with obvious cellular 
‘patterning’ following the vascular network and also ECM structural cues on LIVE/DEAD™ 
staining. Histological analysis again showed cellular engraftment dispersed throughout the 
kidney ECM bioscaffolds with focal areas of recellularisation comparable to normal 
histological density present throughout and distinctive ‘glomerular-like’ structures (Fig. 5a). 
IHC of renal cell markers (as above) were only strongly positive for von Willebrand factor as 
an endothelial cell marker (Fig. 5b). 
Discussion 
Various groups have demonstrated the feasibility of using the whole organ decellularisation 
approach to derive bioengineered (partially) functional organ constructs for surgical 
implantation[14-18]. While there is great interest in the recellularisation potential of these 
bioscaffolds, this potential should be maximised by optimisation of the quality of the ECM 
preserved after perfusion decellularisation. Both donor factors and decellularisation 
parameters should be standardised and rationalised to yield consistent and optimised 
bioscaffolds. Pre-optimisation and standard operating procedures are even more critical 
when it is likely that post-processing testing of the ECM bioscaffold (and the recellularised 
construct) is likely to be limited in scope in those cases destined for implantation. This 
should be the next stage in the evolution of whole organ decellularisation as a potential 
strategy for bioengineered organ replacements. 
Currently, most groups are utilising disparate decellularisation protocols with marked 
variations even in work on the same organ and species[17, 25-29]. Hence we present here 
an evidence-based approach to determining a more systematically assessed protocol for 
whole rat kidney bioscaffolds using a single agent (SDS) with continuous perfusion, as 
defined by preservation of essential ECM components within the bioscaffold. The choice of 
SDS was derived from a systematic review of the whole organ decellularisation literature 
and SDS being the pre-dominant decellularising agent of choice, sometimes in combination 
with Triton-X100 or other agents[22]; SDS was utilised alone within this study as it has been 
well documented to produce complete decellularisation within ECM literature and also for 
purposes of clarity.  
SDS (CH3(CH2)11OSO3Na) is an ionising detergent with molecule amphiphilic properties and 
critical micelle concentration (CMC) is 8.2 mM or approximately 0.23% w/v[30]; it is not pH-
sensitive between pH 5-10. It acts by solubilising cell membranes and nucleic membranes, 
with very effective removal of nuclear remnants and cytoplasmic proteins. However it can 
also denature proteins, remove GAG and growth factors, and cause damage to collagen and 
the ultrastructure of basement membranes[19] – which could have subsequent detrimental 
effects on recellularisation. Whole organ decellularisation with its underlying technique of 
vascular perfusion lends itself well to the principle of minimising SDS exposure since the 
native vascular system allows the maximum efficiency in decellularising agent delivery and 
penetration, especially to dense tissues. Historical protocols traditionally utilising SDS at 1% 
or even higher are not necessarily relevant in this context. Indeed, concentrations above the 
CMC lead to micellar formation of SDS molecules and subsequent plateauing of increased 
detergent efficacy. In addition, SDS residuals may be highly adherent and cytotoxic (with 
subsequent detrimental effects on recellularisation), and hence it would be important for 
these to be quantified in future work e.g. quantification assays of solubilised decellularised 
scaffolds using a colorimetric assay method [31]. Currently this is a significant limitation of 
all extant whole organ decellularisation work utilising SDS. 
Our results have yielded an improved protocol (0.125% w/v SDS perfused for 4 hours) which 
uses a far lower concentration of SDS than other work on whole rat kidney 
decellularisation[18, 23] while being at least as effective in achieving removal of cellular 
components and DNA. The minimum concentration of SDS previously utilised for whole rat 
kidney decellularisation was typically 1%[18], although one study has used 0.5% in porcine 
kidneys[24], and the concentration can be variable up to as high as 4%[23]; no explicit 
justification (or systematic comparative characterisation of decellularised scaffolds) for any 
specific conditions have been stated in any study[18, 23, 24] except for de facto 
demonstration of ‘successful decellularisation’.  
VEGF and bFGF are both highly expressed within the kidney and are vital to both cellular 
proliferation and kidney development. VEGF is expressed by virtually every endothelial cell 
within the kidney[32], which is particularly relevant to the highly intricate vasculature of the 
renal nephron; bFGF is involved in critical functions such as mitogenesis[33]. These two 
growth factors were selected for their importance and ubiquity within the kidney for 
quantitative assessment. Here we have also demonstrated a clear relationship between 
decreasing exposure to SDS (i.e. concentration) and preservation of in situ growth factors, 
down to the level where further decreases in the SDS concentration may not yield 
significantly increased preservation, which has not been previously shown for any whole 
organ bioscaffolds.  
In line with other kidney studies[18, 23], after confirmation of successful decellularisation, 
we have recellularised the whole rat kidney bioscaffolds (by intravascular injection) with 
PRCs and continuous in vitro perfusion and culture for 7 days, leading to viable constructs. 
Histological analysis showed focal areas of dense cellular engraftment with some response 
to kidney ECM structural cues although IHC analysis did not show appropriately localised 
glomerular or tubular cells. We have also achieved comparable findings in recellularisation 
of whole rat kidney bioscaffolds with MSCs, as they are a primary cell population of 
relevance in potential clinical application. MSCs have been observed to have nephrogenic 
potential[34-37] and as they are both sufficiently numerous in the adult and a potentially 
host-derived (and hence immune-tolerant) cell population, they may play a crucial role in 
the clinical translation of bioengineered whole organ constructs. As there was no evidence 
of renal cellular differentiation with histological analysis, we did not proceed with renal 
functional testing.  However, since Song et al recently demonstrated urine production in 
vitro with their recellularisation protocol[18], it is possible that recellularisation with PRCs 
can lead to potentially functional renal regeneration on a whole kidney bioscaffold.  
While we have examined here two fundamental parameters within the decellularisation 
process using SDS for whole rat kidneys, there are many other parameters of significance 
employed within decellularisation protocols as stated before – such as other decellularising 
agents (relevant to the type of tissue in question), additional processes e.g. freezing, use of 
additional agents, tissue harvesting factors, perfusion factors, and post-processing 
sterilisation methods[22]. All these will inevitably affect the quality of the ECM bioscaffold 
to a greater or lesser degree, and these effects have yet to be systematically quantified for 
whole rat kidneys or other organs/species. In addition, while growth factor levels may be 
better preserved by reducing the concentrations of the decellularising agent used (as we 
have demonstrated), functional tests of bioactivity should also be considered for more 
complete characterisation, such as comparative recellularisation studies related to different 
decellularisation parameters[20]. This is another current limitation and major area for 
future improvement. All these factors should play a critical part in developing safe, reliable 
and consistent whole organ bioscaffolds if they are to be taken to the clinical stage in the 
development of regenerated organ replacements. 
In this study, systematic assessment of perfusion decellularisation parameters for whole rat 
kidneys with SDS has led to improved preservation of sGAG and growth factors along with 
minimised exposure to the decellularising agent and its detrimental effects; these whole rat 
kidney bioscaffolds were successfully recellularised with primary renal cells and MSCs to 
yield highly viable constructs. These findings may be applicable to other decellularised 
whole organ/species, and may lead the way to further optimisation and standardisation in 
the development of regenerated organ replacements for transplantation.   
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